Agios Pharmaceuticals Inc (AGIO) 103.51 $AGIO
Insider Trading Alert - AGIO, NXTM And EBIX Traded By Insiders
at The Street - Mon Apr 20, 9:48AM CDT
Stocks with insider trader activity include AGIO, NXTM and EBIX
NXTM: 18.85 (+0.03), EBIX: 29.77 (+0.86), AGIO: 103.51 (-4.12)
Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 5:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5z2hq/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2015" report to their offering. This report provides elemental information and data relating to the clinical trials on Bile Duct Cancer (Cholangiocarcinoma). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bile Duct Cancer (Cholangiocarcinoma). Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials - Sanofi - Eli Lilly and Company - AstraZeneca PLC - GlaxoSmithKline plc - OncoTherapy Science, Inc. - Daiichi Sankyo Company, Limited - CellAct Pharma GmbH - C. H. Boehringer Sohn AG & Co. KG - Astellas US Holding, Inc. - Agios Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/h5...uct_cancer
AZN: 73.35 (+0.65), LLY: 72.30 (+0.09), AGIO: 103.51 (-4.12), GSK: 46.57 (-0.67)
Agios' PK Deficiency Drug AG-348 Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 5:50PM CDT
Agios Pharmaceuticals (AGIO) announced that its PK deficiency candidate, AG-348 has been granted orphan drug status by the FDA.
LCI: 66.45 (-0.28), CBM: 42.07 (-0.65), AGIO: 103.51 (-4.12), CELG: 115.54 (+0.72)
Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency
GlobeNewswire - Tue Mar 24, 2:04PM CDT
- PK deficiency is a severe and rare genetic disease with currently no approved or disease modifying treatments -
AGIO: 103.51 (-4.12)
Jim Cramer -- 19 Companies That Could Get Acquired in 2015
at The Street - Mon Mar 23, 11:35AM CDT
2015 is turning into an epic year for deals. Owning the stock of a likely takeover candidate can result in tidy profits. Jim Cramer names 19 companies to watch.
KMI: 44.07 (+0.46), MNST: 139.91 (+0.06), MDLZ: 36.83 (+0.30), AWAY: 32.27 (+0.76), NKE: 100.15 (-0.14), GRUB: 45.84 (-0.45), GMCR: 114.53 (+2.27), SKX: 75.84 (+1.03), KRFT: 88.25 (-0.22), K: 63.98 (+0.12), JACK: 91.32 (-0.27), YHOO: 43.97 (-0.52), CMG: 641.23 (-51.29), HAWK: 36.12 (+0.28), TWTR: 51.73 (+0.41), Z: 99.00 (+1.96), CST: 43.54 (-0.12), KO: 41.31 (+0.53), BWP: 16.73 (+0.07), NCR: 30.07 (+0.50), VFC: 73.91 (-0.42), TRIP: 82.71 (+1.43), FRGI: 59.39 (-0.22), LULU: 65.67 (-0.68), DRI: 65.20 (-0.09), CELG: 115.54 (+0.72), ADS: 308.33 (+3.47), WWAV: 45.54 (-0.56), HAIN: 61.74 (-0.13), MPC: 102.13 (+2.12), CPB: 46.11 (+0.06), AGIO: 103.51 (-4.12), PAY: 35.88 (-0.06), YELP: 50.45 (+1.14), GIS: 56.21 (+0.10)
Critical Alerts For Advanced Micro Devices, DigitalGlobe, Infoblox, Peabody Energy and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Mar 02, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AMD, DGI, BLOX, BTU and AGIO.
BTU: 4.87 (+0.06), DGI: 33.65 (-0.45), AMD: 2.28 (-0.07), BLOX: 24.25 (+0.11), AGIO: 103.51 (-4.12)
What Makes Agios Pharmaceuticals (AGIO) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:55AM CST
It may not be a good decision to keep Agios Pharmaceuticals (AGIO) in your portfolio anymore, at least if you don’t have a long time horizon to wait
ABAX: 63.25 (-0.09), AGIO: 103.51 (-4.12)
The 1 Stock You've Been Overlooking for Your Roth IRA
Motley Fool Staff - Motley Fool - Fri Feb 20, 6:04AM CST
If you're investing your money through a Roth IRA, you're already on your way to achieving long-term financial security, but don't pat yourself on the back yet. To maximize your Roth IRA, you also need to own the right investments. If you're not sure...
DIS: 107.94 (+0.26), AGIO: 103.51 (-4.12), SPWR: 34.74 (+0.28), CELG: 115.54 (+0.72)
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 18, 5:30PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UIHC: 20.78 (+0.18), SONS: 7.89 (+0.05), HOLI: 23.74 (+0.58), GRMN: 46.95 (-0.62), ORPN: 6.37 (-0.04), SYKE: 24.97 (+0.03), ENPH: 13.38 (+0.03), USTR: 41.62 (+0.15), FOSL: 82.49 (+0.68), AFMD: 7.94 (+0.11), AGIO: 103.51 (-4.12), ISTR: 15.96 (-0.04), BCOR: 13.88 (+0.06), UCTT: 5.66 (+0.14)
Company News for February 18, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 9:10AM CST
Companies in the News are: QSR,WM,LECO,AGIO
QSR: 39.36 (+0.67), AGIO: 103.51 (-4.12), LECO: 66.32 (-0.15), WM: 52.61 (-0.23)
Why Agios Pharmaceuticals Inc Shares Burst Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 17, 4:11PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: shares dropped by more than 10%...
AGIO: 103.51 (-4.12), CELG: 115.54 (+0.72)
Celgene: A Follow-Up To My Bullish Article Of Last Spring
DoctoRx - at Seeking Alpha - Tue Feb 17, 3:09PM CST
AMGN: 169.10 (+0.64), AGIO: 103.51 (-4.12), CELG: 115.54 (+0.72), XLRN: 33.67 (-0.02)
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 17, 11:19AM CST
AGIO: 103.51 (-4.12)
Agios (AGIO) Reports Wider-than-Expected Loss in Q4 - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 17, 8:03AM CST
Agios (AGIO) Reports Wider-than-Expected Loss in Q4
AGIO: 103.51 (-4.12)
Agios Pharma ups revenues 157% in FY14
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 7:18AM CST
AGIO: 103.51 (-4.12)
Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Feb 17, 6:58AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2014. In addition, Agios highlighted selected corporate milestones and updated guidance for its lead clinical development programs:
AGIO: 103.51 (-4.12)
Agios Pharmaceuticals reports 4Q loss
Automated Insights - Tue Feb 17, 6:48AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Tuesday reported a loss of $26.7 million in its fourth quarter.
AGIO: 103.51 (-4.12)
Agios Pharmaceuticals misses by $0.18, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 6:33AM CST
AGIO: 103.51 (-4.12)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 16, 4:30PM CST
MDT: 78.01 (+0.93), GPC: 93.02 (+0.57), WLT: 0.57 (-0.01), PES: 6.26 (-0.24), TGH: 31.21 (-0.04), CRY: 10.11 (-0.08), LECO: 66.32 (-0.15), MGM: 22.03 (+0.32), USAC: 22.00 (unch), MNTA: 18.62 (+0.56), WM: 52.61 (-0.23), TTS: 14.52 (-0.33), ACC: 41.74 (+0.47), QSR: 39.36 (+0.67), VDSI: 25.11 (-0.58), GT: 27.65 (-0.08), WWW: 32.81 (+0.21), WRI: 34.43 (+0.31), ALE: 50.65 (-0.22), AGIO: 103.51 (-4.12), NHI: 68.86 (+0.33), VNR: 15.85 (+0.04)
Insider Trading Alert - AGIO, NXTM And EBIX Traded By Insiders
at The Street - Mon Apr 20, 9:48AM CDT
Stocks with insider trader activity include AGIO, NXTM and EBIX
NXTM: 18.85 (+0.03), EBIX: 29.77 (+0.86), AGIO: 103.51 (-4.12)
Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 5:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5z2hq/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2015" report to their offering. This report provides elemental information and data relating to the clinical trials on Bile Duct Cancer (Cholangiocarcinoma). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bile Duct Cancer (Cholangiocarcinoma). Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials - Sanofi - Eli Lilly and Company - AstraZeneca PLC - GlaxoSmithKline plc - OncoTherapy Science, Inc. - Daiichi Sankyo Company, Limited - CellAct Pharma GmbH - C. H. Boehringer Sohn AG & Co. KG - Astellas US Holding, Inc. - Agios Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/h5...uct_cancer
AZN: 73.35 (+0.65), LLY: 72.30 (+0.09), AGIO: 103.51 (-4.12), GSK: 46.57 (-0.67)
Agios' PK Deficiency Drug AG-348 Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 5:50PM CDT
Agios Pharmaceuticals (AGIO) announced that its PK deficiency candidate, AG-348 has been granted orphan drug status by the FDA.
LCI: 66.45 (-0.28), CBM: 42.07 (-0.65), AGIO: 103.51 (-4.12), CELG: 115.54 (+0.72)
Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency
GlobeNewswire - Tue Mar 24, 2:04PM CDT
- PK deficiency is a severe and rare genetic disease with currently no approved or disease modifying treatments -
AGIO: 103.51 (-4.12)
Jim Cramer -- 19 Companies That Could Get Acquired in 2015
at The Street - Mon Mar 23, 11:35AM CDT
2015 is turning into an epic year for deals. Owning the stock of a likely takeover candidate can result in tidy profits. Jim Cramer names 19 companies to watch.
KMI: 44.07 (+0.46), MNST: 139.91 (+0.06), MDLZ: 36.83 (+0.30), AWAY: 32.27 (+0.76), NKE: 100.15 (-0.14), GRUB: 45.84 (-0.45), GMCR: 114.53 (+2.27), SKX: 75.84 (+1.03), KRFT: 88.25 (-0.22), K: 63.98 (+0.12), JACK: 91.32 (-0.27), YHOO: 43.97 (-0.52), CMG: 641.23 (-51.29), HAWK: 36.12 (+0.28), TWTR: 51.73 (+0.41), Z: 99.00 (+1.96), CST: 43.54 (-0.12), KO: 41.31 (+0.53), BWP: 16.73 (+0.07), NCR: 30.07 (+0.50), VFC: 73.91 (-0.42), TRIP: 82.71 (+1.43), FRGI: 59.39 (-0.22), LULU: 65.67 (-0.68), DRI: 65.20 (-0.09), CELG: 115.54 (+0.72), ADS: 308.33 (+3.47), WWAV: 45.54 (-0.56), HAIN: 61.74 (-0.13), MPC: 102.13 (+2.12), CPB: 46.11 (+0.06), AGIO: 103.51 (-4.12), PAY: 35.88 (-0.06), YELP: 50.45 (+1.14), GIS: 56.21 (+0.10)
Critical Alerts For Advanced Micro Devices, DigitalGlobe, Infoblox, Peabody Energy and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Mar 02, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AMD, DGI, BLOX, BTU and AGIO.
BTU: 4.87 (+0.06), DGI: 33.65 (-0.45), AMD: 2.28 (-0.07), BLOX: 24.25 (+0.11), AGIO: 103.51 (-4.12)
What Makes Agios Pharmaceuticals (AGIO) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:55AM CST
It may not be a good decision to keep Agios Pharmaceuticals (AGIO) in your portfolio anymore, at least if you don’t have a long time horizon to wait
ABAX: 63.25 (-0.09), AGIO: 103.51 (-4.12)
The 1 Stock You've Been Overlooking for Your Roth IRA
Motley Fool Staff - Motley Fool - Fri Feb 20, 6:04AM CST
If you're investing your money through a Roth IRA, you're already on your way to achieving long-term financial security, but don't pat yourself on the back yet. To maximize your Roth IRA, you also need to own the right investments. If you're not sure...
DIS: 107.94 (+0.26), AGIO: 103.51 (-4.12), SPWR: 34.74 (+0.28), CELG: 115.54 (+0.72)
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 18, 5:30PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UIHC: 20.78 (+0.18), SONS: 7.89 (+0.05), HOLI: 23.74 (+0.58), GRMN: 46.95 (-0.62), ORPN: 6.37 (-0.04), SYKE: 24.97 (+0.03), ENPH: 13.38 (+0.03), USTR: 41.62 (+0.15), FOSL: 82.49 (+0.68), AFMD: 7.94 (+0.11), AGIO: 103.51 (-4.12), ISTR: 15.96 (-0.04), BCOR: 13.88 (+0.06), UCTT: 5.66 (+0.14)
Company News for February 18, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 9:10AM CST
Companies in the News are: QSR,WM,LECO,AGIO
QSR: 39.36 (+0.67), AGIO: 103.51 (-4.12), LECO: 66.32 (-0.15), WM: 52.61 (-0.23)
Why Agios Pharmaceuticals Inc Shares Burst Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 17, 4:11PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: shares dropped by more than 10%...
AGIO: 103.51 (-4.12), CELG: 115.54 (+0.72)
Celgene: A Follow-Up To My Bullish Article Of Last Spring
DoctoRx - at Seeking Alpha - Tue Feb 17, 3:09PM CST
AMGN: 169.10 (+0.64), AGIO: 103.51 (-4.12), CELG: 115.54 (+0.72), XLRN: 33.67 (-0.02)
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 17, 11:19AM CST
AGIO: 103.51 (-4.12)
Agios (AGIO) Reports Wider-than-Expected Loss in Q4 - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 17, 8:03AM CST
Agios (AGIO) Reports Wider-than-Expected Loss in Q4
AGIO: 103.51 (-4.12)
Agios Pharma ups revenues 157% in FY14
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 7:18AM CST
AGIO: 103.51 (-4.12)
Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Feb 17, 6:58AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2014. In addition, Agios highlighted selected corporate milestones and updated guidance for its lead clinical development programs:
AGIO: 103.51 (-4.12)
Agios Pharmaceuticals reports 4Q loss
Automated Insights - Tue Feb 17, 6:48AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Tuesday reported a loss of $26.7 million in its fourth quarter.
AGIO: 103.51 (-4.12)
Agios Pharmaceuticals misses by $0.18, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 6:33AM CST
AGIO: 103.51 (-4.12)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 16, 4:30PM CST
MDT: 78.01 (+0.93), GPC: 93.02 (+0.57), WLT: 0.57 (-0.01), PES: 6.26 (-0.24), TGH: 31.21 (-0.04), CRY: 10.11 (-0.08), LECO: 66.32 (-0.15), MGM: 22.03 (+0.32), USAC: 22.00 (unch), MNTA: 18.62 (+0.56), WM: 52.61 (-0.23), TTS: 14.52 (-0.33), ACC: 41.74 (+0.47), QSR: 39.36 (+0.67), VDSI: 25.11 (-0.58), GT: 27.65 (-0.08), WWW: 32.81 (+0.21), WRI: 34.43 (+0.31), ALE: 50.65 (-0.22), AGIO: 103.51 (-4.12), NHI: 68.86 (+0.33), VNR: 15.85 (+0.04)
